Loading...
•
Dec 31, 2022
Sangamo Q4 2022 Earnings Report
Reported recent business highlights and fourth quarter and full year 2022 financial results.
Key Takeaways
Sangamo Therapeutics reported fourth quarter 2022 revenues of $27.2 million and a net loss of $52.0 million, or $0.32 per share. The company highlighted progress in its Fabry disease, renal transplant rejection, sickle cell disease, and hemophilia A programs, and provided initial financial guidance for 2023.
Reported compelling updated preliminary Phase 1/2 data showing extended clinical benefit for Fabry disease.
Progressed manufacturing and clinical activities ahead of anticipated Q2 dosing for Renal Transplant Rejection.
Presented promising 6-month data for first patient dosed with a product candidate manufactured using improved methods for Sickle cell disease.
Dosing in Phase 3 AFFINE trial expected to be complete by end of Q1 2023 for Hemophilia A.
Forward Guidance
Sangamo expects GAAP total operating expenses in the range of approximately $310 million to $330 million in 2023. Non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $35 million, are expected in the range of approximately $275 million to $295 million in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...